Sangamo Therapeutics, Inc
SGMOQ- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001001233
No open-market purchases or sales by Sangamo Therapeutics, Inc insiders were filed in the last 90 days; 6 institutions reported holding it in 13F filings for Q2 2026, worth $29.0K in total; no superinvestor holds it.
13F holders, Q3 2022
Institutional positions in Sangamo Therapeutics, Inc as of Sep 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 197
- +9 vs. Q2 2022
- Shares held
- 97.4M
- +7.68M (+8.6%) vs. Q2 2022
- Total value
- $477.2M
- +$106.2M (+28.6%) vs. Q2 2022
- New holders
- 32
- 67 more added
- Sold out
- 23
- 47 more reduced
Compare with Q2 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting SGMOQ on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 6 | $29.0K |
| Q1 2026 | 112 | $26.0M |
| Q4 2025 | 105 | $26.2M |
| Q3 2025 | 112 | $42.1M |
| Q2 2025 | 114 | $39.6M |
| Q1 2025 | 122 | $34.5M |
| Q4 2024 | 128 | $62.9M |
| Q3 2024 | 103 | $48.6M |
| Q2 2024 | 129 | $31.1M |
| Q1 2024 | 131 | $68.2M |
| Q4 2023 | 130 | $47.2M |
| Q3 2023 | 135 | $61.3M |
| Q2 2023 | 152 | $137.4M |
| Q1 2023 | 180 | $197.6M |
| Q4 2022 | 182 | $326.0M |
| Q3 2022 | 197 | $477.2M |
| Q2 2022 | 188 | $371.1M |
| Q1 2022 | 195 | $459.6M |
| Q4 2021 | 193 | $577.0M |
| Q3 2021 | 193 | $679.3M |
| Q2 2021 | 197 | $912.0M |
| Q1 2021 | 203 | $994.7M |
Institutions, Q3 2022
Shares, value and share of portfolio for each institution holding Sangamo Therapeutics, Inc; share changes are against Q2 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Platinum Investment Management Ltd | 0 | $0 | 0.00% | −218,336−100.0% | Sold out |
| Natixis | 0 | $0 | 0.00% | −181,019−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −120,316−100.0% | Sold out |
| Algert Global LLC | 0 | $0 | 0.00% | −112,740−100.0% | Sold out |
| Caxton Associates LP | 0 | $0 | 0.00% | −88,549−100.0% | Sold out |
| Caption Management, LLC | 0 | $0 | 0.00% | −44,100−100.0% | Sold out |
| Shell Asset Management Co | 0 | $0 | 0.00% | −42,138−100.0% | Sold out |
| Delphia (USA) Inc. | 0 | $0 | 0.00% | −31,498−100.0% | Sold out |
| Bayesian Capital Management, LP | 0 | $0 | 0.00% | −31,000−100.0% | Sold out |
| Corton Capital Inc. | 0 | $0 | 0.00% | −28,707−100.0% | Sold out |
| Handelsbanken Fonder AB | 0 | $0 | 0.00% | −28,246−100.0% | Sold out |
| Point72 Hong Kong Ltd | 0 | $0 | 0.00% | −28,019−100.0% | Sold out |
| Balyasny Asset Management LLC | 0 | $0 | 0.00% | −25,900−100.0% | Sold out |
| Private Advisor Group, LLC | 0 | $0 | 0.00% | −12,631−100.0% | Sold out |
| Kestra Advisory Services, LLC | 0 | $0 | 0.00% | −11,518−100.0% | Sold out |
| Bourgeon Capital Management LLC | 0 | $0 | 0.00% | −2,550−100.0% | Sold out |
| Arlington Partners LLC | 0 | $0 | 0.00% | −2,000−100.0% | Sold out |
| Captrust Financial Advisors | 0 | $0 | 0.00% | −1,238−100.0% | Sold out |
| Rockbridge Investment Management, LCC | 0 | $0 | 0.00% | −905−100.0% | Sold out |
| Banque Cantonale Vaudoise | 0 | $0 | 0.00% | −93−100.0% | Sold out |